Virchows Archiv

, Volume 472, Issue 1, pp 125–133 | Cite as

Immune checkpoint inhibitor colitis: the flip side of the wonder drugs

  • Naziheh Assarzadegan
  • Elizabeth Montgomery
  • Robert A. Anders
Invited Annual Review Issue


Immune checkpoint inhibitors block the co-inhibitory receptors on T cells to activate their cytotoxic immune function and are rapidly being explored for the treatment of various advanced-stage malignancies. These novel drugs have already significantly increased survival rates. The first available immune checkpoint inhibitors were cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors (such as ipilimumab), followed by programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) inhibitors (such as pembrolizumab and nivolumab). Anti-PD-1 and anti-PD-L1 therapies have demonstrated better efficacy and tolerability and less severe adverse effects compared to anti-CTLA-4 agents. Idelalisib, a PI3Kδ isoform inhibitor, is another immunotherapeutic agent that is often classified separately and is currently used in treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomas. Despite successful therapeutic responses, immune-related adverse events have been reported with the use of these agents. The gastrointestinal side effects, particularly diarrhea, are among the most commonly reported symptoms. The histologic features of immune checkpoint inhibitor-associated colitis show a spectrum of patterns of injury among various drug classes. There is significant overlap between immune checkpoint inhibitor-associated colitis and other colitides, making the differential diagnosis difficult—especially in the absence of clinical history. The histopathology data on immune checkpoint inhibitor-associated colitis are limited. Here we review clinical features as well as various histologic patterns of colitis associated with these groups of medications.


Colitis Immune checkpoint inhibitors PD-L1 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588(2):368–376. CrossRefPubMedGoogle Scholar
  2. 2.
    Dolan DE, Gupta S (2014) PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 21(3):231–237. CrossRefPubMedGoogle Scholar
  3. 3.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz l Jr et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2016) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 27(7):1362. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. CrossRefPubMedGoogle Scholar
  8. 8.
    Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. CrossRefPubMedGoogle Scholar
  9. 9.
    Mitchel KA, Kluger H, Sznol M, Hartman DJ (2013) Ipilimumab-induced perforating colitis. J Clin Gastroenterol 47(9):781–785. CrossRefGoogle Scholar
  10. 10.
    Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240. CrossRefPubMedGoogle Scholar
  11. 11.
    Chen JH, Pezhouh MK, Lauwers GY, Masia R (2017) Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 41(5):643–654. CrossRefPubMedGoogle Scholar
  12. 12.
    Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY (2008) α-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 32(8):1130–1137. CrossRefPubMedGoogle Scholar
  13. 13.
    Gupta A, De Felice KM, Loftus EV, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42(4):406–417. CrossRefPubMedGoogle Scholar
  14. 14.
    Weidner A-S, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, Jessurun J, Yantiss RK (2015) Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol 39(12):1661–1667. CrossRefPubMedGoogle Scholar
  15. 15.
    Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C (2017) PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology 70(4):558–567. CrossRefPubMedGoogle Scholar
  16. 16.
    Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129(2):512–521. CrossRefPubMedGoogle Scholar
  17. 17.
    Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–209. CrossRefPubMedGoogle Scholar
  18. 18.
    Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675–1682. CrossRefPubMedGoogle Scholar
  19. 19.
    Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4(14):272.  10.21037/atm.2016.07.10 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbe C (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164. CrossRefPubMedGoogle Scholar
  22. 22.
    Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4(5):560–575. PubMedPubMedCentralGoogle Scholar
  23. 23.
    Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: Clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39(12):1653–1660. CrossRefPubMedGoogle Scholar
  24. 24.
    McDermott DF, Atkins MB (2013) PD-1 as a potential target in cancer therapy. Cancer Med 2(5):662–673. PubMedPubMedCentralGoogle Scholar
  25. 25.
    Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297–339. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    West NR, Powrie F (2015) Immunotherapy not working? Check your microbiota. Cancer Cell 28(6):687–689. CrossRefPubMedGoogle Scholar
  28. 28.
    Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD et al (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94(9):4330–4335. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hude I, Sasse S, Engert A, Bröckelmann PJ (2017) The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 102(1):30–42. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB et al (2010) Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 55(5):1396–1405. CrossRefPubMedGoogle Scholar
  31. 31.
    Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK et al (2016) Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 14(6):836–842. CrossRefPubMedGoogle Scholar
  32. 32.
    Bavi P, Butler M, Serra S, Chetty R (2017) Immune modulator-induced changes in the gastrointestinal tract. Histopathology 71(3):494–496. CrossRefPubMedGoogle Scholar
  33. 33.
    Baroudjian B, Lourenco N, Pages C, Chami I, Maillet M, Bertheau P, Bagot M, Gornet JM, Lebbe C, Allez M (2016) Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res 26(3):308–311. CrossRefPubMedGoogle Scholar
  34. 34.
    Marginean EC (2016) The ever-changing landscape of drug-induced injury of the lower gastrointestinal tract. Arch Pathol Lab Med 140(8):748–758. CrossRefPubMedGoogle Scholar
  35. 35.
    Arnold CA, Lam-Himlin DM, Montgomery E (2015) Atlas of gastrointestinal pathology: a pattern based approach to non-neoplastic biopsies. Wolters Kluwer Health, PhiladelphiaGoogle Scholar
  36. 36.
    Beck KE, Blansfield JA, Tran KQ, Feldman a, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24(15):2283–2289. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Fecher LA, Agarwala SS, Hodi FS, Weber JS (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18(6):733–743. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Fay AP, Moreira RB, Nunes Filho PR, Albuquerque C, Barrios CH (2016) The management of immune-related adverse events associated with immune checkpoint blockade. Expert Rev Qual Life Cancer Care 1(1):89–97. CrossRefGoogle Scholar
  39. 39.
    Johnston RL, Lutzky J, Chodhry A, Barkin JS (2009) Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 54(11):2538–2540. CrossRefPubMedGoogle Scholar
  40. 40.
    Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Vieth M, Montgomery E (2017) Medication-associated gastrointestinal tract injury. Virchows Arch 470(3):245–266. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.University of FloridaGainesvilleUSA
  2. 2.Johns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations